The U.S. Food and Drug Administration (FDA) approved Eli Lilly’s supplemental new drug application (sNDA) for Humalog(R) (insulin lispro injection [rDNA origin]).
Based on the updated label, people with type 1 diabetes using Humalog for pump therapy can use the insulin in the pump reservoir for up to seven days and should change the infusion set and infusion set insertion site at least every three days. The previous label indicated that Humalog in the external insulin pump reservoir should be replaced and a new infusion site selected every 48 hours or less.
